Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860240 | 0.93 | KDM4E (0.57) | KDM4EPKMUSP30GPR119CCR8 | |
| SCHEMBL18838335 | 0.89 | USP30 (0.53) | KDM4EPKMUSP30GPR119CCR8 | |
| SCHEMBL19995715 | 0.83 | STS (0.46) | KDM4EPKMGPR119KMT2AMEN1 | |
| SCHEMBL18838507 | 0.82 | KEAP1 (0.49) | KDM4EPKMGPR119TSHRALOX15 | |
| SCHEMBL13199301 | 0.79 | KDM4E (0.68) | KDM4EPKMUSP30GPR119CCR8 | |
| SCHEMBL18860279 | 0.78 | CARM1 (0.46) | KMT2AMEN1 | |
| SCHEMBL18860274 | 0.77 | KMT2A (0.43) | PKMKMT2AMEN1 | |
| SCHEMBL19995750 | 0.76 | STS (0.48) | KDM4EPKMGPR119KMT2AMEN1 | |
| SCHEMBL18838432 | 0.76 | CYP2D6 (0.43) | KMT2AMEN1ATM | |
| SCHEMBL18860275 | 0.75 | DRD4 (0.54) | KMT2AHDAC1HDAC8HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-108289886-B | Ion channel inhibiting compounds, pharmaceutical formulations and uses | 安华赛公司 | 2022-01-28 | — | — | CN | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3340988-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | Afasci, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | KDM4E 2152/4885PKM 2309/4885USP30 3823/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | KDM4E 2152/4885PKM 2309/4885USP30 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.